

James B Galloway

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2984090/publications.pdf>

Version: 2024-02-01

174
papers

5,740
citations

126708

33
h-index

88477

70
g-index

183
all docs

183
docs citations

183
times ranked

8547
citing authors

#	ARTICLE	IF	CITATIONS
1	A Knowledge Distillation Ensemble Framework for Predicting Short- and Long-Term Hospitalization Outcomes From Electronic Health Records Data. IEEE Journal of Biomedical and Health Informatics, 2022, 26, 423-435.	3.9	5
2	Inpatient COVID-19 mortality has reduced over time: Results from an observational cohort. PLoS ONE, 2022, 17, e0261142.	1.1	23
3	Rates and predictors of methotrexate-related adverse events in patients with early rheumatoid arthritis: results from a nationwide UK study. Rheumatology, 2022, 61, 3930-3938.	0.9	13
4	Vaccine hesitancy and access to psoriasis care during the COVID-19 pandemic: findings from a global patient-reported cross-sectional survey. British Journal of Dermatology, 2022, 187, 254-256.	1.4	11
5	When should we start screening for hydroxychloroquine retinopathy?. Rheumatology, 2022, 61, 3097-3098.	0.9	1
6	Skeletal muscles and Covid-19: a systematic review of rhabdomyolysis and myositis in SARS-CoV-2 infection. Clinical and Experimental Rheumatology, 2022, 40, 329-338.	0.4	33
7	Hospitalizations for Acute Gout: Process Mapping the Inpatient Journey and Identifying Predictors of Admission. Journal of Rheumatology, 2022, 49, 725-730.	1.0	2
8	JAK inhibitors: special issue foreword. Expert Review of Clinical Immunology, 2022, 18, 179-180.	1.3	1
9	British Society for Rheumatology guideline on management of paediatric, adolescent and adult patients with idiopathic inflammatory myopathy. Rheumatology, 2022, 61, 1760-1768.	0.9	37
10	The impact of COVID-19 on clinical care, self-management and mental health of patients with inflammatory arthritis. Rheumatology Advances in Practice, 2022, 6, rkab095.	0.3	10
11	The infection risks of JAK inhibition. Expert Review of Clinical Immunology, 2022, 18, 253-261.	1.3	21
12	P022 Audit of vitamin D and calcium level monitoring in sarcoidosis patients taking calcium and/or vitamin D supplements. Rheumatology, 2022, 61, .	0.9	0
13	P099 Invasive listeriosis in patients with immune-mediated inflammatory diseases on biologics and targeted therapies - a review of the literature. Rheumatology, 2022, 61, .	0.9	0
14	P223 Predictors of mortality in idiopathic inflammatory myopathy-associated interstitial lung disease - a systematic review and meta-analysis. Rheumatology, 2022, 61, .	0.9	0
15	P074 Evaluation of incidence of COVID-19 infection and uptake of COVID-19 vaccine in sarcoidosis patients at a tertiary centre. Rheumatology, 2022, 61, .	0.9	0
16	Worse outcomes linked to ethnicity for early inflammatory arthritis in England and Wales: a national cohort study. Rheumatology, 2022, 62, 169-180.	0.9	4
17	Venous Thromboembolism Risk With JAK Inhibitors: A Meta-Analysis. Arthritis and Rheumatology, 2021, 73, 779-788.	2.9	86
18	A cross-sectional study of sleep and depression in a rheumatoid arthritis population. Clinical Rheumatology, 2021, 40, 1299-1305.	1.0	17

#	ARTICLE	IF	CITATIONS
19	COVID-19 and mortality in rare rheumatic diseases, a warning bell?. <i>Rheumatology</i> , 2021, 60, 1580-1581.	0.9	2
20	Baseline retinal testing is no longer recommended for hydroxychloroquine users in the United Kingdom. <i>Rheumatology</i> , 2021, 60, 2037-2039.	0.9	1
21	Remote Measurement in Rheumatoid Arthritis: Qualitative Analysis of Patient Perspectives. <i>JMIR Formative Research</i> , 2021, 5, e22473.	0.7	6
22	P049â€fSkeletal muscle involvement in COVID-19 infection: a case report and systematic review. <i>Rheumatology</i> , 2021, 60, .	0.9	2
23	Demyelinating Events Following Initiation of Anti-TNF± Therapy in the British Society for Rheumatology Biologics Registry in Rheumatoid Arthritis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	3.1	16
24	P090â€fValidation of hospital episode statistics data to enable national registration of idiopathic inflammatory myopathies. <i>Rheumatology</i> , 2021, 60, .	0.9	1
25	The safety of JAK-1 inhibitors. <i>Rheumatology</i> , 2021, 60, ii24-ii30.	0.9	59
26	Systematic Review and Metaanalysis of the Reproducibility of Patient Self-reported Joint Counts in Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2021, 48, jrheum.201439.	1.0	5
27	IL-6 inhibition in the treatment of COVID-19: A meta-analysis and meta-regression. <i>Journal of Infection</i> , 2021, 82, 178-185.	1.7	37
28	Recurrent acute pericarditis diagnosed by extra-cellular volume maps. <i>European Heart Journal</i> , 2021, , .	1.0	0
29	The COVID-19 Vaccine Landscape: What a Rheumatologist Needs to Know. <i>Journal of Rheumatology</i> , 2021, 48, 1201-1204.	1.0	5
30	Epidemiology of Scleritis in the United Kingdom From 1997 to 2018: Populationâ€Based Analysis of 11 Million Patients and Association Between Scleritis and Infectious and Immuneâ€Mediated Inflammatory Disease. <i>Arthritis and Rheumatology</i> , 2021, 73, 1267-1276.	2.9	25
31	Investigating Pleiotropy Between Depression and Autoimmune Diseases Using the UK Biobank. <i>Biological Psychiatry Global Open Science</i> , 2021, 1, 48-58.	1.0	29
32	Improving outcomes for patients hospitalized with gout: a systematic review. <i>Rheumatology</i> , 2021, 61, 90-102.	0.9	5
33	Nonserious Infections in Patients With Rheumatoid Arthritis: Results From the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2021, 73, 1800-1809.	2.9	18
34	Intensive therapy for moderate established rheumatoid arthritis: the TITRATE research programme. <i>Programme Grants for Applied Research</i> , 2021, 9, 1-186.	0.4	1
35	Endothelin antagonism and sodium glucose Co-transporter 2 inhibition. A potential combination therapeutic strategy for COVID-19. <i>Pulmonary Pharmacology and Therapeutics</i> , 2021, 69, 102035.	1.1	9
36	Exploring the macro-level, meso-level and micro-level barriers and facilitators to the provision of good quality early inflammatory arthritis (EIA) care in England and Wales. <i>RMD Open</i> , 2021, 7, e001616.	1.8	4

#	ARTICLE	IF	CITATIONS
37	Diarrhoea and preadmission antibiotic exposure in COVID-19: a retrospective cohort study of 1153 hospitalised patients. <i>BMJ Open Gastroenterology</i> , 2021, 8, e000593.	1.1	1
38	Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine. <i>New England Journal of Medicine</i> , 2021, 385, 1172-1183.	13.9	734
39	Chest radiography is a poor predictor of respiratory symptoms and functional impairment in survivors of severe COVID-19 pneumonia. <i>ERJ Open Research</i> , 2021, 7, 00655-2020.	1.1	109
40	COVID-19-related acute kidney injury; incidence, risk factors and outcomes in a large UK cohort. <i>BMC Nephrology</i> , 2021, 22, 359.	0.8	31
41	Herpes zoster and Janus kinase inhibition in rheumatology and gastroenterology patients: managing risk and vaccination. <i>Clinical and Experimental Rheumatology</i> , 2021, , .	0.4	0
42	The relationship between citations, downloads and alternative metrics in rheumatology publications: a bibliometric study. <i>Rheumatology</i> , 2020, 59, 277-280.	0.9	21
43	Placebo Response in Rheumatoid Arthritis Clinical Trials. <i>Journal of Rheumatology</i> , 2020, 47, 28-34.	1.0	24
44	Rising Incidence of Acute Hospital Admissions due to Gout. <i>Journal of Rheumatology</i> , 2020, 47, 619-623.	1.0	21
45	The use of real-world data to address questions of patient safety. <i>Rheumatology</i> , 2020, 59, 26-30.	0.9	3
46	Cardiovascular risk in ankylosing spondylitis and the effect of anti-TNF drugs: a narrative review. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 517-524.	1.4	35
47	Variation and implications of treatment decisions in early rheumatoid arthritis: results from a nationwide cohort study. <i>Rheumatology</i> , 2020, 59, 2035-2042.	0.9	8
48	EP44â€fTaking eosinophilia more seriously. <i>Rheumatology</i> , 2020, 59, .	0.9	0
49	O26â€fNon-serious infections in patients with RA: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. <i>Rheumatology</i> , 2020, 59, .	0.9	1
50	P192â€fCrystallising care: improving hospital gout management. <i>Rheumatology</i> , 2020, 59, .	0.9	0
51	P228â€fRisk of sinusitis in patients with rheumatoid arthritis: association with different treatment strategies. <i>Rheumatology</i> , 2020, 59, .	0.9	0
52	COVID-19: opacification score is higher in the right lung and right lung involvement is a better predictor of ICU admission. <i>European Respiratory Journal</i> , 2020, 56, 2002340.	3.1	5
53	Trends in Optic Neuritis Incidence and Prevalence in the UK and Association With Systemic and Neurologic Disease. <i>JAMA Neurology</i> , 2020, 77, 1514.	4.5	45
54	EP13â€fA case of candida albicans septic sacroiliitisâ€f complicating severe COVID-19 infection. <i>Rheumatology Advances in Practice</i> , 2020, 4, .	0.3	1

#	ARTICLE	IF	CITATIONS
55	The impact of disease severity and duration on cost, early retirement and ability to work in rheumatoid arthritis in Europe: an economic modelling study. <i>Rheumatology Advances in Practice</i> , 2020, 4, rkaa041.	0.3	10
56	O19â€fSecukinumab-related gastrointestinal safety in PsA and AS. <i>Rheumatology</i> , 2020, 59, .	0.9	0
57	P65â€fExploring ethnic disparities in early arthritis care. <i>Rheumatology</i> , 2020, 59, .	0.9	0
58	P110â€fDeveloping a digital interface for outpatient rheumatology. <i>Rheumatology</i> , 2020, 59, .	0.9	0
59	muLTi-Arm Therapeutic study in pre-ICu patients admitted with Covid-19-Experimental drugs and mechanisms (TACTIC-E): A structured summary of a study protocol for a randomized controlled trial. <i>Trials</i> , 2020, 21, 690.	0.7	14
60	The clinical effectiveness of intensive management in moderate established rheumatoid arthritis: The titrate trial. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 1182-1190.	1.6	10
61	Overview of IgG4-related aortitis and periaortitis. A decade since their first description. <i>Autoimmunity Reviews</i> , 2020, 19, 102694.	2.5	25
62	How achievable are COVID-19 clinical trial recruitment targets? A UK observational cohort study and trials registry analysis. <i>BMJ Open</i> , 2020, 10, e044566.	0.8	11
63	NEIAA: driving EIA service quality in a shifting clinical landscape. <i>Rheumatology</i> , 2020, 59, 3127-3128.	0.9	3
64	A case-control and cohort study to determine the relationship between ethnic background and severe COVID-19. <i>EClinicalMedicine</i> , 2020, 28, 100574.	3.2	48
65	A systematic review of CXCL13 as a biomarker of disease and treatment response in rheumatoid arthritis. <i>BMC Rheumatology</i> , 2020, 4, 70.	0.6	12
66	Study of entheses in patients with spondyloarthritis and inflammatory bowel disease with and without fibromyalgia: The importance of ultrasonography. <i>Joint Bone Spine</i> , 2020, 87, 507-508.	0.8	2
67	A clinical risk score to identify patients with COVID-19 at high risk of critical care admission or death: An observational cohort study. <i>Journal of Infection</i> , 2020, 81, 282-288.	1.7	179
68	Poor outcome and prolonged persistence of SARSâ€CoVâ€2 RNA in COVIDâ€19 patients with haematological malignancies; King's College Hospital experience. <i>British Journal of Haematology</i> , 2020, 190, e279-e282.	1.2	89
69	Adaptations to the British Society of Gastroenterology guidelines on the management of acute severe UC in the context of the COVID-19 pandemic: a RAND appropriateness panel. <i>Gut</i> , 2020, 69, gutjnl-2020-321927.	6.1	28
70	Defining and measuring imaging appropriateness in low back pain studies: a scoping review. <i>European Spine Journal</i> , 2020, 29, 519-529.	1.0	14
71	Rheumatology care of migrants from sub-Saharan Africa: a literature review and qualitative pilot study of patientsâ€™ perspectives. <i>Clinical Rheumatology</i> , 2020, 40, 3429-3438.	1.0	1
72	Data quality predicts care quality: findings from a national clinical audit. <i>Arthritis Research and Therapy</i> , 2020, 22, 87.	1.6	11

#	ARTICLE	IF	CITATIONS
73	185â€¦A clinical risk score to identify patients with COVID-19 at high risk of critical care admission or death: An observational cohort study. <i>Emergency Medicine Journal</i> , 2020, 37, 843.3-844.	0.4	1
74	EP23â€¦Symptomatic sarcoid myopathy: a rare extra-pulmonary manifestation of sarcoidosis. <i>Rheumatology Advances in Practice</i> , 2020, 4, .	0.3	0
75	EP21â€¦Tumour necrosis factor inhibitor for the treatment of refractory extra-pulmonary disease including sarcoid arthritis and myositis. <i>Rheumatology Advances in Practice</i> , 2020, 4, .	0.3	1
76	Italian recommendations for influenza and pneumococcal vaccination in adult patients with autoimmune rheumatic diseases. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 245-256.	0.4	2
77	Better is possible. <i>Rheumatology</i> , 2019, 58, 741-742.	0.9	0
78	The price of good health care. <i>Rheumatology</i> , 2019, 58, 931-932.	0.9	1
79	Validation of the Musculoskeletal Health Questionnaire in inflammatory arthritis: a psychometric evaluation. <i>Rheumatology</i> , 2019, 58, 45-51.	0.9	13
80	The new entries in the therapeutic armamentarium: The small molecule JAK inhibitors. <i>Pharmacological Research</i> , 2019, 147, 104392.	3.1	62
81	Cochrane corner: why we still donâ€™t know whether anti-TNF biologic therapies impact uveitic macular oedema. <i>Eye</i> , 2019, 33, 1830-1832.	1.1	4
82	17.â€¦Tick-borne relapsing fever: a fever syndrome mimic. <i>Rheumatology Advances in Practice</i> , 2019, 3, .	0.3	0
83	075â€¦Summary of findings from the Burden of Rheumatoid Arthritis across Europe Socioeconomic Survey (BRASS). <i>Rheumatology</i> , 2019, 58, .	0.9	0
84	209â€¦Quantifying care variation: the keystone of national quality improvement. <i>Rheumatology</i> , 2019, 58, .	0.9	0
85	E023â€¦The use of CXCL13 as a biomarker in rheumatoid arthritis: a systematic review. <i>Rheumatology</i> , 2019, 58, .	0.9	1
86	Reply. <i>Arthritis and Rheumatology</i> , 2019, 71, 1025-1026.	2.9	0
87	I004â€¦Initial findings from the National Early Inflammatory Arthritis Audit. <i>Rheumatology</i> , 2019, 58, .	0.9	0
88	Centre effects and case-mix in early rheumatoid arthritis observational cohorts: a narrative review. <i>Rheumatology</i> , 2019, 58, 1991-1999.	0.9	1
89	145â€¦The British Society for Rheumatologyâ€™s Choosing Wisely UK recommendations. <i>Rheumatology</i> , 2019, 58, .	0.9	0
90	214â€¦If I tweet more about my paper, will I improve my citation index?. <i>Rheumatology</i> , 2019, 58, .	0.9	1

#	ARTICLE	IF	CITATIONS
91	Polypharmacy is associated with treatment response and serious adverse events: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. <i>Rheumatology</i> , 2019, 58, 1767-1776.	0.9	24
92	A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis. <i>Rheumatology</i> , 2019, 58, 1755-1766.	0.9	201
93	Mobile apps, wearables and the future of technology in rheumatic disease care. <i>Rheumatology</i> , 2019, 58, 1126-1127.	0.9	7
94	Determining responsiveness and meaningful changes for the Musculoskeletal Health Questionnaire (MSK-HQ) for use across musculoskeletal care pathways. <i>BMJ Open</i> , 2019, 9, e025357.	0.8	17
95	AB0372â€¦EXPLORING REFRACTORY DISEASE & PERSISTENT SYMPTOMS IN RA/POLYJIA DESPITE BDMARDS: PATIENT & PROFESSIONAL EXPERIENCES. , 2019, , .		0
96	AB0553â€¦STUDY OF ANXIETY AND DEPRESSION IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE). , 2019, , .		0
97	AB0247â€¦INSIGHTS INTO ADHERENCE AND PATIENT-INITIATED MONOTHERAPY FOR RHEUMATOID ARTHRITIS VIA A GLOBAL SURVEY OF PATIENTS, CAREGIVERS AND PHYSICIANS. , 2019, , .		0
98	Small-Molecule Protein Kinases Inhibitors and the Risk of Fungal Infections. <i>Current Fungal Infection Reports</i> , 2019, 13, 229-243.	0.9	11
99	Monitoring for retinal toxicity in patients taking hydroxychloroquine and chloroquine. <i>Rheumatology</i> , 2019, 58, 3-4.	0.9	15
100	Opportunistic infections in rheumatoid arthritis patients exposed to biologic therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. <i>Rheumatology</i> , 2018, 57, 997-1001.	0.9	82
101	The relationship between depression and biologic treatment response in rheumatoid arthritis: An analysis of the British Society for Rheumatology Biologics Register. <i>Rheumatology</i> , 2018, 57, 835-843.	0.9	83
102	Comment on: Managing varicella zoster virus contact and infection in patients on anti-rheumatic therapy. <i>Rheumatology</i> , 2018, 57, 768-768.	0.9	2
103	Pulmonary Sarcoidosis in a patient with Multiple Sclerosis on daclizumab monotherapy. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 20, 25-27.	0.9	5
104	Twitter, #alternativefacts, careless whispers and Rheumatology. <i>Rheumatology</i> , 2018, 57, 773-774.	0.9	7
105	Depressive symptoms, pain and disability for adolescent patients with juvenile idiopathic arthritis: results from the Childhood Arthritis Prospective Study. <i>Rheumatology</i> , 2018, 57, 1381-1389.	0.9	52
106	Serious infection across biologic-treated patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, annrheumdis-2017-212825.	0.5	115
107	The evidence base for psychological interventions for rheumatoid arthritis: A systematic review of reviews. <i>International Journal of Nursing Studies</i> , 2018, 82, 20-29.	2.5	65
108	A Systematic Review and Metaanalysis of Antirheumatic Drugs and Vaccine Immunogenicity in Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2018, 45, 733-744.	1.0	82

#	ARTICLE	IF	CITATIONS
109	A review of the musculoskeletal manifestations of sarcoidosis. <i>Rheumatology</i> , 2018, 57, 777-783.	0.9	56
110	The RA-MAP Consortium: a working model for academia–industry collaboration. <i>Nature Reviews Rheumatology</i> , 2018, 14, 53-60.	3.5	15
111	Return of the king: rising incidence of gout in England 2006-2017 (Young investigator award) <i>Tj ETQq1 1 0,784314 rgBT /Over</i>	0.9	0
112	Mental health, fatigue and function are associated with increased risk of disease flare following TNF inhibitor tapering in patients with rheumatoid arthritis: an exploratory analysis of data from the Optimizing TNF Tapering in RA (OPTTIRA) trial. <i>RMD Open</i> , 2018, 4, e000676.	1.8	14
113	Sporotrichosis of the tongue. <i>Rheumatology Advances in Practice</i> , 2018, 2, .	0.3	0
114	National Arthritis Audit IT portal. <i>Rheumatology</i> , 2018, 57, .	0.9	0
115	Hydroxychloroquine use, risk of retinal toxicity, and potential impact of screening in a large tertiary centre. <i>Rheumatology</i> , 2018, 57, .	0.9	0
116	The impact of the EIA clinic on early RA care. <i>Rheumatology</i> , 2018, 57, .	0.9	0
117	Comparison of patient and physician perspectives in the management of rheumatoid arthritis: results from global physician- and patient-based surveys. <i>Health and Quality of Life Outcomes</i> , 2018, 16, 211.	1.0	30
118	Differentiating Disease Flare From Infection: A Common Problem in Rheumatology. Do 18F-FDG PET/CT Scans and Novel Biomarkers Hold The Answer?. <i>Current Rheumatology Reports</i> , 2018, 20, 70.	2.1	3
119	Flares in Rheumatoid Arthritis Patients with Low Disease Activity: Predictability and Association with Worse Clinical Outcomes. <i>Journal of Rheumatology</i> , 2018, 45, 1515-1521.	1.0	40
120	Liver function abnormalities on conventional DMARDs: results from a contemporary cohort. <i>Rheumatology</i> , 2018, 57, .	0.9	1
121	The Impact of Targeted Rheumatoid Arthritis Pharmacologic Treatment on Mental Health. <i>Arthritis and Rheumatology</i> , 2018, 70, 1377-1391.	2.9	39
122	The Royal College of Ophthalmologists recommendations on screening for hydroxychloroquine and chloroquine users in the United Kingdom: executive summary. <i>Eye</i> , 2018, 32, 1168-1173.	1.1	52
123	Managing varicella zoster virus contact and infection in patients on anti-rheumatic therapy. <i>Rheumatology</i> , 2018, 57, 596-605.	0.9	12
124	Risk of lymphoma in patients exposed to antitumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 497-503.	0.5	88
125	Patient involvement in rheumatology outpatient service design and delivery: a case study. <i>Health Expectations</i> , 2017, 20, 508-518.	1.1	25
126	BSR and BHPR guideline for the prescription and monitoring of non-biologic disease-modifying anti-rheumatic drugs. <i>Rheumatology</i> , 2017, 56, 865-868.	0.9	106

#	ARTICLE	IF	CITATIONS
127	Diagnostic yield of FDG-PET/CT in fever of unknown origin: a systematic review, meta-analysis, and Delphi exercise. <i>Clinical Radiology</i> , 2017, 72, 764-771.	0.5	63
128	Smoking and common mental disorders in patients with chronic conditions: An analysis of data collected via a web-based screening system. <i>General Hospital Psychiatry</i> , 2017, 45, 12-18.	1.2	20
129	Polypharmacy and Unplanned Hospitalizations in Patients with Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2017, 44, 1786-1793.	1.0	25
130	Optimizing treatment with tumour necrosis factor inhibitors in rheumatoid arthritis—a proof of principle and exploratory trial: is dose tapering practical in good responders?. <i>Rheumatology</i> , 2017, 56, 2004-2014.	0.9	27
131	Patient- and clinician-reported outcomes for patients with new presentation of inflammatory arthritis: observations from the National Clinical Audit for Rheumatoid and Early Inflammatory Arthritis. <i>Rheumatology</i> , 2017, 56, 231-238.	0.9	10
132	Achievement of NICE quality standards for patients with new presentation of inflammatory arthritis: observations from the National Clinical Audit for Rheumatoid and Early Inflammatory Arthritis. <i>Rheumatology</i> , 2017, 56, 223-230.	0.9	16
133	Response to: “Does the risk of lymphoma in patients with RA treated with TNF inhibitors differ according to the histological subtype and the type of TNF inhibitor?” by Nocturne et al. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, e4-e4.	0.5	2
134	Does intensive management improve remission rates in patients with intermediate rheumatoid arthritis? (the TITRATE trial): study protocol for a randomised controlled trial. <i>Trials</i> , 2017, 18, 591.	0.7	14
135	The evidence for biologic immunotherapy in Sarcoidosis: A systematic review. <i>Australasian Medical Journal</i> , 2017, 10, .	0.1	0
136	The spectrum of early rheumatoid arthritis practice across the globe: results from a multinational cross sectional survey. <i>Clinical and Experimental Rheumatology</i> , 2017, 35, 477-483.	0.4	5
137	114 “Experiences of Treatment Decision-Making and Self-Management for Working-Age People with Symptomatic Osteoarthritis of the Knee. <i>Rheumatology</i> , 2016, , .	0.9	0
138	091 “Rationalising the Treatment Target in Rheumatoid Arthritis: Defining the Optimal 28-Joint DAS Cut-Off to Determine Good Function and Normal Health-Related Quality of Life. <i>Rheumatology</i> , 2016, , .	0.9	0
139	028 “The Incidence and Predictors of Flare in a Cohort of Rheumatoid Arthritis Patients. <i>Rheumatology</i> , 2016, , .	0.9	0
140	Components of treatment delay in rheumatoid arthritis differ according to autoantibody status: validation of a single-centre observation using national audit data. <i>Rheumatology</i> , 2016, 55, 1843-1848.	0.9	23
141	Patients’ and carers’ views and expectations about intensive management for moderate rheumatoid arthritis: a qualitative study. <i>Psychology, Health and Medicine</i> , 2016, 21, 918-925.	1.3	9
142	Biosimilars in rheumatology: out of the laboratory and into practice. <i>Expert Review of Clinical Immunology</i> , 2016, 12, 697-699.	1.3	3
143	A large two-centre study in to rates of influenza and pneumococcal vaccination and infection burden in rheumatoid arthritis in the UK. <i>BMC Musculoskeletal Disorders</i> , 2016, 17, 322.	0.8	43
144	The first national clinical audit for rheumatoid arthritis. <i>British Journal of Nursing</i> , 2016, 25, 613-617.	0.3	10

#	ARTICLE	IF	CITATIONS
145	A population study of the reported incidence of native joint septic arthritis in the United Kingdom between 1998 and 2013. <i>Rheumatology</i> , 2016, 55, 2176-2180.	0.9	39
146	Rheumatoid arthritis – an update for general dental practitioners. <i>British Dental Journal</i> , 2016, 221, 667-673.	0.3	10
147	Optimal responses in disease activity scores to treatment in rheumatoid arthritis: Is a DAS28 reduction of >1.2 sufficient?. <i>Arthritis Research and Therapy</i> , 2016, 18, 142.	1.6	7
148	Changing clinical patterns in rheumatoid arthritis management over two decades: sequential observational studies. <i>BMC Musculoskeletal Disorders</i> , 2016, 17, 44.	0.8	19
149	Is there a role of synovial biopsy in drug development?. <i>BMC Musculoskeletal Disorders</i> , 2016, 17, 172.	0.8	9
150	Cardiovascular risk with NSAIDs in rheumatoid arthritis: an analysis using routinely collected data. <i>Rheumatology</i> , 2016, 55, 763-764.	0.9	9
151	Predictors of objective cough frequency in pulmonary sarcoidosis. <i>European Respiratory Journal</i> , 2016, 47, 1461-1471.	3.1	43
152	Motivational interviewing: relevance in the treatment of rheumatoid arthritis?. <i>Rheumatology</i> , 2016, 55, 1348-1356.	0.9	29
153	How to manage patients'™ expectations in rheumatoid arthritis treatment. <i>International Journal of Clinical Rheumatology</i> , 2015, 10, 301-303.	0.3	3
154	Mitigating infection risk with immunotherapy for rheumatoid arthritis. <i>International Journal of Clinical Rheumatology</i> , 2015, 10, 177-193.	0.3	4
155	108. – Review of the Inclusion Criteria of Clinical Trials in PSA with a Comparison with Routine Care Cohort. <i>Rheumatology</i> , 2015, , .	0.9	0
156	Inflammatory Arthritis in Clinical Practice. , 2015, , .		2
157	Extreme elevation of ferritin and creatine kinase in primary infection with HIV-1. <i>International Journal of STD and AIDS</i> , 2015, 26, 68-71.	0.5	11
158	Delivering Future Clinical Trials in Rheumatology. <i>Journal of Rheumatology</i> , 2015, 42, 18-20.	1.0	1
159	The ying and yang of fever in rheumatic disease. <i>Clinical Medicine</i> , 2015, 15, 288-291.	0.8	8
160	Anti-Tumour Necrosis Factor-Alpha (TNF- α) Treatment. , 2015, , 119-135.		0
161	The risk of gastrointestinal perforations in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the BSRBR-RA. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 252-255.	0.5	21
162	A Threshold Hazard Model for Estimating Serious Infection Risk Following Anti-Tumor Necrosis Factor Therapy in Rheumatoid Arthritis Patients. <i>Journal of Biopharmaceutical Statistics</i> , 2013, 23, 461-476.	0.4	3

#	ARTICLE	IF	CITATIONS
163	Investigation of Rheumatoid Arthritis Genetic Susceptibility Markers in the Early Rheumatoid Arthritis Study Further Replicates the <i>TRAF1</i> Association with Radiological Damage. <i>Journal of Rheumatology</i> , 2013, 40, 144-156.	1.0	22
164	Risk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 229-234.	0.5	146
165	Risk of cancer in patients receiving non-biologic disease-modifying therapy for rheumatoid arthritis compared with the UK general population. <i>Rheumatology</i> , 2013, 52, 91-98.	0.9	116
166	Anti-TNF therapy in women with rheumatoid arthritis with a history of carcinoma in situ of the cervix: Table 1. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 143-144.	0.5	30
167	The influence of anti-TNF therapy upon incidence of keratinocyte skin cancer in patients with rheumatoid arthritis: longitudinal results from the British Society for Rheumatology Biologics Register. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 869-874.	0.5	107
168	Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. <i>Rheumatology</i> , 2011, 50, 124-131.	0.9	564
169	Risk of septic arthritis in patients with rheumatoid arthritis and the effect of anti-TNF therapy: results from the British Society for Rheumatology Biologics Register. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1810-1814.	0.5	173
170	Venous thrombotic events are not increased in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1831-1834.	0.5	62
171	The risk of serious infections in patients receiving anakinra for rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. <i>Rheumatology</i> , 2011, 50, 1341-1342.	0.9	43
172	Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 522-528.	0.5	606
173	€fThe Increasing Incidence of Septic Arthritis in England Between 1998 and 2013. <i>Rheumatology</i> , 0, , .	0.9	0
174	Herpes zoster and Janus kinase inhibition in rheumatology and gastroenterology patients: managing risk and vaccination. <i>Clinical and Experimental Rheumatology</i> , 0, , .	0.4	3